U.S. Physical Therapy Reports First Quarter 2022 Results
U.S. Physical Therapy (USPH) reported strong Q1 2022 results with net income of $8.8 million, up from $8.2 million year-over-year. Earnings per diluted share increased to $0.67 from $0.21. Total revenue reached $131.7 million, a 17.2% rise, while adjusted EBITDA grew 14.2% to $17.9 million. Patient visits increased by 12.2%, totaling over 1 million. The company declared a quarterly dividend of $0.41 per share payable on June 14, 2022. A significant acquisition of a six-clinic practice was also completed, enhancing growth prospects.
- Net income increased by 7.3% to $8.8 million.
- Earnings per diluted share rose to $0.67 from $0.21.
- Total revenue surged 17.2% to $131.7 million.
- Adjusted EBITDA increased 14.2% to $17.9 million.
- Total patient visits grew by 12.2%, exceeding 1 million.
- Industrial injury prevention services revenue hit an all-time high of $19.1 million, up 90.5% year-over-year.
- Acquired a six-clinic practice generating over $7.5 million in annual revenue.
- Net patient revenue per visit declined to $103.00 from $104.72 due to Medicare rate reductions.
- Total operating costs rose to 79.8% of revenue, up from 77.0% in the prior year.
- Management contract revenue fell by 13.0% to $2.2 million.
Declares Quarterly Dividend
HIGHLIGHTS
-
Operating Results per diluted share, a non-GAAP measure (defined below), was
per diluted share for the 2022 First Quarter as compared to$0.65 for the three months ended$0.64 March 31, 2021 (“2021 First Quarter”). -
For the 2022 First Quarter, USPH’s net income attributable to its shareholders, a Generally Accepted Accounting Principles (“GAAP”) measure, was
compared to$8.8 million for the 2021 First Quarter. GAAP requires the Company to include a charge for the revaluation of its non-controlling interest, net of taxes, in its computation of earnings per diluted share. Earnings per diluted share on a GAAP basis, was$8.2 million for the 2022 First Quarter as compared to$0.67 for the 2021 First Quarter.$0.21 -
Adjusted EBITDA, a non-GAAP measure (defined below), was
for the 2022 First Quarter, a$17.9 million 14.2% increase from for the 2021 First Quarter. See pages 10 through 11 for a discussion and reconciliation to results according to GAAP.$15.6 million - Average visits per clinic per day in the 2022 First Quarter was 27.9, up from 27.1 in the 2021 First Quarter.
-
Total patient visits were 1,063,519 for the 2022 First Quarter, an increase of
12.2% from 947,788 for the 2021 First Quarter. On a same store basis, visits increased5.9% in the 2022 First Quarter as compared to the 2021 First Quarter. -
The net rate per patient visit was
in the 2022 First Quarter as compared to$103.00 in the 2021 First Quarter due to rate reductions implemented by Medicare in 2022.$104.72 -
Net patient revenue from physical therapy operations was
for the 2022 First Quarter, an increase of$109.5 million 10.4% from for the 2021 First Quarter.$99.3 million -
Industrial injury prevention (“IIP”) services revenue was an all-time high of
for the 2022 First Quarter, representing a$19.1 million 90.5% increase over the 2021 First Quarter. Excluding of revenue related to the$6.8 million November 2021 IIP acquisition, IIP services revenue increased22.4% period over period. -
Total revenue of
for the 2022 First Quarter was$131.7 million 17.2% higher than total revenue of for the 2021 First Quarter.$112.4 million -
Physical therapy operating costs were
per visit in the 2022 First Quarter as compared to$83.09 in the 2021 First Quarter, an increase of$81.18 2.4% . On a same store basis, physical therapy operating costs per visit increased0.4% to in the 2022 First Quarter from$81.08 in the 2021 First Quarter.$80.78 -
Total operating cost was
79.8% of total revenue in the 2022 First Quarter, as compared to77.0% for the 2021 First Quarter. Total salaries and related costs were57.1% of total revenue for the 2022 First Quarter versus56.8% for the 2021 First Quarter. -
On
March 31, 2022 , the Company acquired70.0% of the equity interest in a six-clinic physical therapy practice inSouth Central Pennsylvania (Madden & Gilbert Physical Therapy, LLC ). The business generates more than in annual revenue and has approximately 71,000 patient visits per year.$7.5 million -
The Company’s Board of Directors declared a quarterly dividend of
per share payable on$0.41 June 14, 2022 to shareholders of record onMay 16, 2022 .
SUMMARY OF FIRST QUARTER RESULTS
For the 2022 First Quarter, the Company’s net income attributable to its shareholders was
For the 2022 First Quarter, the Company’s Operating Results, a non-GAAP measure, was
First Quarter 2022 Compared to First Quarter 2021
-
Reported total revenue for the 2022 First Quarter was
, an increase of$131.7 million 17.2% as compared to for the 2021 First Quarter. See table below for a detail of reported total revenue (in thousands):$112.4 million
|
|
Three Months Ended |
|
|||||
|
|
|
|
|
|
|
||
Revenue related to |
|
$ |
102,321 |
|
|
$ |
98,649 |
|
Revenue related to 2022 Clinic Additions |
|
|
195 |
|
|
|
- |
|
Revenue related to 2021 Clinic Additions |
|
|
6,823 |
|
|
|
149 |
|
Revenue from clinics sold or closed in 2022 |
|
|
199 |
|
|
|
190 |
|
Revenue from clinics sold or closed in 2021 |
|
|
- |
|
|
|
266 |
|
Net patient revenue from physical therapy operations |
|
|
109,538 |
|
|
|
99,254 |
|
Other revenue |
|
|
872 |
|
|
|
546 |
|
Revenue from physical therapy operations |
|
|
110,410 |
|
|
|
99,800 |
|
Revenue from management contracts |
|
|
2,226 |
|
|
|
2,559 |
|
Revenue from industrial injury prevention services |
|
|
19,068 |
|
|
|
10,009 |
|
Total Revenue |
|
$ |
131,704 |
|
|
$ |
112,368 |
|
-
Revenue from physical therapy operations increased
, or$10.6 million 10.6% , to for the 2022 First Quarter from$110.4 million for the 2021 First Quarter. Net patient revenue related to clinics opened or acquired prior to 2021 and still in operation at$99.8 million March 31, 2022 (“Mature Clinics”) increased , or$3.7 million 3.7% , to for the 2022 First Quarter compared to$102.3 million for the 2021 First Quarter.$98.6 million
-
The average net patient revenue per visit was
for the 2022 First Quarter as compared to$103.00 for the 2021 First Quarter. Total patient visits increased$104.72 12.2% to 1,063,519 for the 2022 First Quarter from 947,788 for the 2021 First Quarter. Visits forMature Clinics (same store) for the 2022 First Quarter increased5.9% as compared to the 2021 First Quarter.
-
Management contract revenue decreased
13.0% to for the 2022 First Quarter as compared to$2.2 million for the 2021 First Quarter.$2.6 million
-
IIP services revenue increased
90.5% to for the 2022 First Quarter as compared to$19.1 million for the 2021 First Quarter. Excluding$10.0 million of revenue related to the IIP acquisition in$6.8 million November 2021 , IIP services revenue increased22.4% in the 2022 First Quarter as compared to the 2021 First Quarter
-
Total operating cost was
for the 2022 First Quarter, or$105.1 million 79.8% of total revenue, as compared to , or$86.5 million 77.0% of total revenue, for the 2021 First Quarter. Operating cost related toMature Clinics increased by for the 2022 First Quarter compared to the 2021 First Quarter. On a per visit basis, operating cost related to$4.8 million Mature Clinics increased0.4% from in the 2021 First Quarter to$80.78 in the 2022 First Quarter. In addition, operating cost related to the industrial injury prevention services business increased by$81.08 of which$7.6 million related to the recent IIP acquisition. See table below for a detail of operating cost (in thousands):$5.6 million
|
|
Three Months Ended |
|
|||||
|
|
|
|
|
|
|
||
Operating cost related to |
|
$ |
81,034 |
|
|
$ |
76,221 |
|
Operating cost related to 2022 Clinic Additions |
|
|
840 |
|
|
|
- |
|
Operating cost related to 2021 Clinic Additions |
|
|
6,209 |
|
|
|
136 |
|
Operating cost related to clinics sold or closed in 2022 |
|
|
286 |
|
|
|
249 |
|
Operating cost related to clinics sold or closed in 2021 |
|
|
- |
|
|
|
334 |
|
Operating cost related to physical therapy operations |
|
|
88,369 |
|
|
|
76,940 |
|
Operating cost related to management contracts |
|
|
1,831 |
|
|
|
2,245 |
|
Operating cost related to industrial injury prevention services |
|
|
14,916 |
|
|
|
7,287 |
|
Total operating cost |
|
$ |
105,116 |
|
|
$ |
86,472 |
|
|
|
|
|
|
|
|
|
|
-
Total salaries and related costs, including all operations, were
57.1% of total revenue for the 2022 First Quarter versus56.8% for the 2021 First Quarter. Rent, supplies, contract labor and other costs as a percentage of total revenue were21.8% for the 2022 First Quarter versus19.1% for the 2021 First Quarter. The provision for credit losses as a percentage of total revenue was1.0% for 2022 First Quarter and1.1% for 2021 First Quarter.
-
Gross profit for the 2022 First Quarter, was
, an increase of$26.6 million , or approximately$0.7 million 2.7% , as compared to for the 2021 First Quarter. The gross profit percentage was$25.9 million 20.2% of total revenue for the 2022 First Quarter as compared to23.0% for the 2021 First Quarter. The gross profit percentage for the Company’s physical therapy operations was20.0% for the 2022 First Quarter as compared to22.9% for the 2021 First Quarter. The gross profit percentage on management contracts was17.7% for the 2022 First Quarter as compared to12.3% for the 2021 First Quarter. The gross profit percentage for industrial injury prevention services was21.8% for the 2022 First Quarter as compared to27.2% for the 2021 First Quarter. The table below details the gross profit (in thousands):
|
|
Three Months Ended |
|
|||||
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
||
Physical therapy operations |
|
$ |
22,041 |
|
|
$ |
22,860 |
|
Management contracts |
|
|
395 |
|
|
|
314 |
|
Industrial injury prevention services |
|
|
4,152 |
|
|
|
2,722 |
|
Gross profit |
|
$ |
26,588 |
|
|
$ |
25,896 |
|
|
|
|
|
|
|
|
|
|
-
Corporate office costs were
for the 2022 First Quarter compared to$11.6 million for the 2021 First Quarter. Corporate office costs were$10.9 million 8.8% of total revenue for the 2022 First Quarter as compared to9.7% for the 2021 First Quarter.
-
Operating income for the 2022 First Quarter and 2021 First Quarter was
. Operating income as a percentage of total revenue was$15.0 million 11.4% for the 2022 First Quarter as compared to13.4% for the 2021 First Quarter.
-
The gain on revaluation of put-right liability was
. As part of the IIP business acquisition on$603,000 November 30, 2021 , the Company also agreed to the potential future purchase of a separate company under the same ownership that provides physical therapy and rehabilitation services to hospitals and other ancillary providers in a distinct market area. The owners have the right to put this transaction to the Company in approximately five years, with such right having a value at$2.9 million March 31, 2022 , as reflected on the Company’s consolidated balance sheet in Other long-term liabilities. The value of this right will continue to be adjusted in future periods, as appropriate.
-
The provision for income tax was
for the 2022 First Quarter and$3.5 million for the 2021 First Quarter. The provision for income tax as a percentage of income before taxes less net income attributable to non-controlling interest (effective tax rate) was$2.9 million 28.6% for the 2022 First Quarter and26.5% for the 2021 First Quarter. See table below ($ in thousands):
|
|
Three Months Ended |
|
|||||
|
|
|
|
|
|
|
||
Income before taxes |
|
$ |
15,480 |
|
|
$ |
14,830 |
|
Less: net income attributable to non-controlling interest: |
|
|
|
|
|
|
|
|
Redeemable non-controlling interest - temporary equity |
|
|
(2,557 |
) |
|
|
(2,453 |
) |
Non-controlling interest - permanent equity |
|
|
(626 |
) |
|
|
(1,260 |
) |
|
|
$ |
(3,183 |
) |
|
$ |
(3,713 |
) |
Income before taxes less net income attributable to non-controlling interest |
|
$ |
12,297 |
|
|
$ |
11,117 |
|
Provision for income taxes |
|
$ |
3,498 |
|
|
$ |
2,944 |
|
Percentage |
|
|
28.4 |
% |
|
|
26.5 |
% |
|
|
|
|
|
|
|
|
|
-
Net income attributable to redeemable non-controlling interest (temporary equity) was
for the 2022 First Quarter and$2.6 million for the 2021 First Quarter. Net income attributable to non-controlling interest (permanent equity) was$2.5 million for the 2022 First Quarter and$0.6 million for the 2021 First Quarter.$1.3 million
Other Financial Measures
For the 2022 First Quarter, the Company’s Adjusted EBITDA, a non-GAAP measure, was
Medicare Accelerated and Advance Payment Program (“MAAPP Funds”)
On
The CARES Act allowed for qualified healthcare providers to receive advanced payments under the MAAPP Funds during the COVID-19 pandemic. Under this program, healthcare providers could choose to receive advanced payments for future Medicare services provided. The Company applied for and received approval from
Acquisition in First Quarter 2022
On
The Company’s strategy is to continue acquiring multi-clinic outpatient physical therapy practices, to develop outpatient physical therapy clinics as satellites in existing partnerships and to continue acquiring companies that provide industrial injury prevention services.
Quarterly Dividend
The Board of Directors declared a quarterly dividend of
Management’s Comments
First Quarter 2022 Conference Call
Forward-Looking Statements
This press release contains statements that are considered to be forward-looking within the meaning under Section 21E of the Securities Exchange Act of 1934, as amended. These statements contain forward-looking information relating to the financial condition, results of operations, plans, objectives, future performance and business of our Company. These statements (often using words such as “believes”, “expects”, “intends”, “plans”, “appear”, “should” and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we expect. Included among such statements may be those relating to new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to:
- the multiple effects of the impact of public health crises and epidemics/pandemics, such as the novel strain of COVID-19 and its variants, for which the total financial magnitude cannot be currently estimated;
- changes in Medicare rules and guidelines and reimbursement or failure of our clinics to maintain their Medicare certification and/or enrollment status;
- revenue we receive from Medicare and Medicaid being subject to potential retroactive reduction;
- changes in reimbursement rates or payment methods from third party payors including government agencies, and changes in the deductibles and co-pays owed by patients;
- compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply;
- competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
- the impact of COVID-19 related vaccination and/or testing mandates at the federal, state and/or local level, which could have an adverse impact on staffing, revenue, costs and the results of operations;
- changes as the result of government enacted national healthcare reform;
- business and regulatory conditions including federal and state regulations;
- governmental and other third party payor inspections, reviews, investigations and audits, which may result in sanctions or reputational harm and increased costs;
- revenue and earnings expectations;
- legal actions, which could subject us to increased operating costs and uninsured liabilities;
- general economic conditions;
- availability and cost of qualified physical therapists;
- personnel productivity and retaining key personnel;
- competitive environment in the industrial injury prevention services business, which could result in the termination or nonrenewal of contractual service arrangements and other adverse financial consequences for that service line;
- acquisitions, and the successful integration of the operations of the acquired businesses;
- impact on the business and cash reserves resulting from retirement or resignation of key partners and resulting purchase of their non-controlling interest (minority interests);
- maintaining our information technology systems with adequate safeguards to protect against cyber-attacks;
- a security breach of our or our third party vendors’ information technology systems may subject us to potential legal action and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 of the Health Information Technology for Economic and Clinical Health Act;
- maintaining clients for which we perform management and other services, as a breach or termination of those contractual arrangements by such clients could cause operating results to be less than expected;
- maintaining adequate internal controls;
- maintaining necessary insurance coverage;
- availability, terms, and use of capital; and
- weather and other seasonal factors.
See Risk Factors in Item 1A of our Annual Report on Form 10-K for the year ended
Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. Please see the other sections of this report and our other periodic reports filed with the
About
Founded in 1990,
More information about
CONSOLIDATED STATEMENTS OF INCOME (IN THOUSANDS, EXCEPT PER SHARE DATA) (unaudited) |
||||||||
|
|
Three Months Ended |
|
|||||
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
||
Net patient revenue |
|
$ |
109,538 |
|
|
$ |
99,254 |
|
Other revenue |
|
|
22,166 |
|
|
|
13,114 |
|
Net revenue |
|
|
131,704 |
|
|
|
112,368 |
|
Operating cost: |
|
|
|
|
|
|
|
|
Salaries and related costs |
|
|
75,149 |
|
|
|
63,815 |
|
Rent, supplies, contract labor and other |
|
|
28,662 |
|
|
|
21,457 |
|
Provision for credit losses |
|
|
1,305 |
|
|
|
1,200 |
|
Total operating cost |
|
|
105,116 |
|
|
|
86,472 |
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
|
26,588 |
|
|
|
25,896 |
|
|
|
|
|
|
|
|
|
|
Corporate office costs |
|
|
11,556 |
|
|
|
10,874 |
|
Operating income |
|
|
15,032 |
|
|
|
15,022 |
|
|
|
|
|
|
|
|
|
|
Other income and expense |
|
|
|
|
|
|
|
|
Equity in earnings of unconsolidated affiliate |
|
|
339 |
|
|
|
- |
|
Interest and other income, net |
|
|
46 |
|
|
|
54 |
|
Gain on revaluation of put-right liability |
|
|
603 |
|
|
|
- |
|
Interest expense - debt and other |
|
|
(540 |
) |
|
|
(246 |
) |
Total other income and expense |
|
|
448 |
|
|
|
(192 |
) |
Income before taxes |
|
|
15,480 |
|
|
|
14,830 |
|
|
|
|
|
|
|
|
|
|
Provision for income taxes |
|
|
3,498 |
|
|
|
2,944 |
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
11,982 |
|
|
|
11,886 |
|
|
|
|
|
|
|
|
|
|
Less: net income attributable to non-controlling interest: |
|
|
|
|
|
|
|
|
Redeemable non-controlling interest - temporary equity |
|
|
(2,557 |
) |
|
|
(2,453 |
) |
Non-controlling interest - permanent equity |
|
|
(626 |
) |
|
|
(1,260 |
) |
|
|
|
(3,183 |
) |
|
|
(3,713 |
) |
|
|
|
|
|
|
|
|
|
Net income attributable to USPH shareholders |
|
$ |
8,799 |
|
|
$ |
8,173 |
|
|
|
|
|
|
|
|
|
|
Basic and diluted earnings per share attributable to USPH shareholders |
|
$ |
0.67 |
|
|
$ |
0.21 |
|
|
|
|
|
|
|
|
|
|
Shares used in computation - basic and diluted |
|
|
12,937 |
|
|
|
12,870 |
|
|
|
|
|
|
|
|
|
|
Dividends declared per common share |
|
$ |
0.41 |
|
|
$ |
0.35 |
|
|
|
|
|
|
|
|
|
|
CONSOLIDATED BALANCE SHEET (IN THOUSANDS, EXCEPT PER SHARE DATA) |
||||||||
|
|
|
|
|
|
|
||
ASSETS |
|
(unaudited) |
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
24,229 |
|
|
$ |
28,567 |
|
Patient accounts receivable, less allowance for credit losses of |
|
|
49,335 |
|
|
|
46,272 |
|
Accounts receivable - other |
|
|
18,239 |
|
|
|
16,144 |
|
Other current assets |
|
|
4,040 |
|
|
|
4,183 |
|
Total current assets |
|
|
95,843 |
|
|
|
95,166 |
|
Fixed assets: |
|
|
|
|
|
|
|
|
Furniture and equipment |
|
|
60,205 |
|
|
|
58,743 |
|
Leasehold improvements |
|
|
40,541 |
|
|
|
39,194 |
|
Fixed assets, gross |
|
|
100,746 |
|
|
|
97,937 |
|
Less accumulated depreciation and amortization |
|
|
76,601 |
|
|
|
74,958 |
|
Fixed assets, net |
|
|
24,145 |
|
|
|
22,979 |
|
Operating lease right-of-use assets |
|
|
94,243 |
|
|
|
96,427 |
|
Investment in unconsolidated affiliate |
|
|
12,422 |
|
|
|
12,215 |
|
|
|
|
443,692 |
|
|
|
434,679 |
|
Other identifiable intangible assets, net |
|
|
91,546 |
|
|
|
86,382 |
|
Other assets |
|
|
1,972 |
|
|
|
1,578 |
|
Total assets |
|
$ |
763,863 |
|
|
$ |
749,426 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST, USPH SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTEREST |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable - trade |
|
$ |
3,272 |
|
|
$ |
3,268 |
|
Accounts payable - due to seller of acquired business |
|
|
3,203 |
|
|
|
3,203 |
|
Accrued expenses |
|
|
51,121 |
|
|
|
45,705 |
|
Current portion of operating lease liabilities |
|
|
30,625 |
|
|
|
30,475 |
|
Current portion of notes payable |
|
|
799 |
|
|
|
830 |
|
Total current liabilities |
|
|
89,020 |
|
|
|
83,481 |
|
Notes payable, net of current portion |
|
|
4,128 |
|
|
|
3,587 |
|
Revolving line of credit |
|
|
118,000 |
|
|
|
114,000 |
|
Deferred taxes |
|
|
16,067 |
|
|
|
14,385 |
|
Operating lease liabilities, net of current portion |
|
|
72,162 |
|
|
|
74,185 |
|
Other long-term liabilities |
|
|
4,262 |
|
|
|
7,345 |
|
Total liabilities |
|
|
303,639 |
|
|
|
296,983 |
|
|
|
|
|
|
|
|
|
|
Redeemable non-controlling interest - temporary equity |
|
|
158,008 |
|
|
|
155,262 |
|
Commitments and Contingencies |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock, |
|
|
- |
|
|
|
- |
|
Common stock, |
|
|
|
|
|
|
|
|
15,206,173 and 15,126,160 shares issued, respectively |
|
|
151 |
|
|
|
151 |
|
Additional paid-in capital |
|
|
105,205 |
|
|
|
102,688 |
|
Retained earnings |
|
|
227,243 |
|
|
|
224,395 |
|
|
|
|
(31,628 |
) |
|
|
(31,628 |
) |
Total USPH shareholders’ equity |
|
|
300,971 |
|
|
|
295,606 |
|
Non-controlling interest - permanent equity |
|
|
1,245 |
|
|
|
1,575 |
|
Total USPH shareholders' equity and non-controlling interest - permanent equity |
|
|
302,216 |
|
|
|
297,181 |
|
Total liabilities, redeemable non-controlling interest, |
|
|
|
|
|
|
|
|
USPH shareholders' equity and non-controlling interest - permanent equity |
|
$ |
763,863 |
|
|
$ |
749,426 |
|
CONSOLIDATED STATEMENTS OF CASH FLOWS (IN THOUSANDS, EXCEPT PER SHARE DATA) (unaudited) |
||||||||
|
|
Three Months Ended |
|
|||||
|
|
|
|
|
|
|
||
OPERATING ACTIVITIES |
|
|
|
|
|
|
||
Net income including non-controlling interest and earnings from unconsolidated affiliates, net |
|
$ |
11,982 |
|
|
$ |
11,886 |
|
Adjustments to reconcile net income including non-controlling interest to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
3,824 |
|
|
|
2,681 |
|
Provision for credit losses |
|
|
1,305 |
|
|
|
1,200 |
|
Equity-based awards compensation expense |
|
|
1,846 |
|
|
|
1,651 |
|
Deferred income taxes |
|
|
2,132 |
|
|
|
2,181 |
|
Gain on revaluation of put-right liability |
|
|
(603 |
) |
|
|
- |
|
Earnings in unconsolidated affiliate |
|
|
(339 |
) |
|
|
- |
|
Other |
|
|
93 |
|
|
|
96 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
Increase in patient accounts receivable |
|
|
(4,676 |
) |
|
|
(4,688 |
) |
(Increase) decrease in accounts receivable - other |
|
|
(2,145 |
) |
|
|
220 |
|
(Increase) decrease in other assets |
|
|
(735 |
) |
|
|
221 |
|
Increase in accounts payable and accrued expenses |
|
|
1,445 |
|
|
|
3,969 |
|
Decrease in other long-term liabilities |
|
|
(2,480 |
) |
|
|
(1,743 |
) |
Net cash provided by operating activities |
|
|
11,649 |
|
|
|
17,674 |
|
INVESTING ACTIVITIES |
|
|
|
|
|
|
|
|
Purchase of fixed assets |
|
|
(2,528 |
) |
|
|
(1,608 |
) |
Purchase of majority interest in businesses, net of cash acquired |
|
|
(11,242 |
) |
|
|
(11,747 |
) |
Purchase of redeemable non-controlling interest, temporary equity |
|
|
(2,211 |
) |
|
|
|
|
Purchase of non-controlling interest, permanent equity |
|
|
(99 |
) |
|
|
|
|
Proceeds on sales of partnership interest, clinics and fixed assets |
|
|
4 |
|
|
|
152 |
|
Distributions from unconsolidated affiliate |
|
|
132 |
|
|
|
- |
|
Sales of non-controlling interest-permanent |
|
|
- |
|
|
|
- |
|
Net cash used in investing activities |
|
|
(15,944 |
) |
|
|
(13,203 |
) |
FINANCING ACTIVITIES |
|
|
|
|
|
|
|
|
Distributions to non-controlling interest, permanent and temporary equity |
|
|
(3,711 |
) |
|
|
(5,265 |
) |
Cash dividends paid to shareholders |
|
|
- |
|
|
|
- |
|
Proceeds from revolving line of credit |
|
|
35,000 |
|
|
|
60,000 |
|
Payments on revolving line of credit |
|
|
(31,000 |
) |
|
|
(60,000 |
) |
Principal payments on notes payable |
|
|
(332 |
) |
|
|
(145 |
) |
(Payment) receipt of Medicare Accelerated and Advance Funds |
|
|
- |
|
|
|
(14,054 |
) |
Other |
|
|
- |
|
|
|
12 |
|
Net cash used in financing activities |
|
|
(43 |
) |
|
|
(19,452 |
) |
Net decrease in cash and cash equivalents |
|
|
(4,338 |
) |
|
|
(14,981 |
) |
Cash and cash equivalents - beginning of period |
|
|
28,567 |
|
|
|
32,918 |
|
Cash and cash equivalents - end of period |
|
$ |
24,229 |
|
|
$ |
17,937 |
|
|
|
|
|
|
|
|
|
|
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION |
|
|
|
|
|
|
|
|
Cash paid during the period for: |
|
|
|
|
|
|
|
|
Income taxes |
|
$ |
81 |
|
|
$ |
62 |
|
Interest paid |
|
$ |
525 |
|
|
$ |
298 |
|
Non-cash investing and financing transactions during the period: |
|
|
|
|
|
|
|
|
Purchase of businesses - seller financing portion |
|
$ |
300 |
|
|
$ |
300 |
|
Notes payable related to purchase of redeemable non-controlling interest, temporary equity |
|
$ |
246 |
|
|
$ |
4,829 |
|
Notes payable due to purchase of non-controlling interest, permanent equity |
|
$ |
296 |
|
|
$ |
- |
|
Notes receivable related to sale of partnership interest - redeemable non-controlling interest |
|
$ |
- |
|
|
$ |
287 |
|
Dividends payable to USPH shareholders |
|
$ |
5,327 |
|
|
$ |
4,514 |
|
NON-GAAP MEASURES
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(unaudited)
The following tables provide detail of the diluted earnings per share computation and reconcile net income attributable to USPH shareholders calculated in accordance with GAAP to Operating Results and Adjusted EBITDA. Management believes providing Operating Results and Adjusted EBITDA to investors is useful information for comparing the Company's period-to-period results.
Operating Results, a non-GAAP measure, equals net income attributable to USPH shareholders per the consolidated statements of income less the gain on the revaluation of the put-right liability. In accordance with GAAP, the revaluation of redeemable non-controlling interest, net of tax, is included in the earnings per basic and diluted share calculation, although it is not included in net income but charged directly to retained earnings.
Adjusted EBITDA is defined as net income attributable to USPH shareholders before interest income, interest expense, taxes, depreciation, amortization, gain on revaluation of put-right liability and equity-based awards compensation expense. Management believes reporting Adjusted EBITDA is useful information for investors in comparing the Company’s period-to-period results as well as comparing with similar businesses which report adjusted EBITDA as defined by their company.
Management uses Operating Results and Adjusted EBITDA, which eliminates certain items described above that can be subject to volatility and unusual costs, as one the principal measures to evaluate and monitor financial performance period over period. Management believes that Operating Results and Adjusted EBITDA is useful information for investors to use in comparing the Company's period-to-period results as well as for comparing with other similar businesses since most do not have redeemable instruments and therefore have different equity structures.
Operating Results and Adjusted EBITDA are not measures of financial performance under GAAP. Adjusted EBITDA and Operating Results should not be considered in isolation or as an alternative to, or substitute for, net income attributable to USPH shareholders presented in the consolidated financial statements.
OPERATING RESULTS AND ADJUSTED EBITDA 2022 PERIODS COMPARED TO 2021 PERIODS (IN THOUSANDS, EXCEPT PER SHARE DATA) (unaudited) |
||||||||
|
|
Three Months Ended |
|
|||||
|
|
2022 |
|
|
2021 |
|
||
Computation of earnings per share - USPH shareholders: |
|
|
|
|
|
|
||
Net income attributable to USPH shareholders |
|
$ |
8,799 |
|
|
$ |
8,173 |
|
Credit (charges) to retained earnings: |
|
|
|
|
|
|
|
|
Revaluation of redeemable non-controlling interest |
|
|
(153 |
) |
|
|
(7,270 |
) |
Tax effect at statutory rate (federal and state) of |
|
|
39 |
|
|
|
1,857 |
|
|
|
$ |
8,685 |
|
|
$ |
2,760 |
|
|
|
|
|
|
|
|
|
|
Earnings per share (basic and diluted) |
|
$ |
0.67 |
|
|
$ |
0.21 |
|
|
|
|
|
|
|
|
|
|
Adjustments: |
|
|
|
|
|
|
|
|
Gain on revaluation of put-right liability |
|
|
(603 |
) |
|
|
- |
|
Revaluation of redeemable non-controlling interest |
|
|
153 |
|
|
|
7,270 |
|
Tax effect at statutory rate (federal and state) |
|
|
115 |
|
|
|
(1,857 |
) |
Operating Results (a non-GAAP measure) |
|
$ |
8,350 |
|
|
$ |
8,173 |
|
|
|
|
|
|
|
|
|
|
Basic and diluted Operating Results per share (a non-GAAP measure) |
|
$ |
0.65 |
|
|
$ |
0.64 |
|
|
|
|
|
|
|
|
|
|
Shares used in computation - basic and diluted |
|
|
12,937 |
|
|
|
12,870 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|||||
|
|
2022 |
|
|
2021 |
|
||
|
|
|
|
|
|
|
|
|
Net income attributable to USPH shareholders |
|
$ |
8,799 |
|
|
$ |
8,173 |
|
|
|
|
|
|
|
|
|
|
Adjustments: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
3,824 |
|
|
|
2,681 |
|
Interest income |
|
|
(46 |
) |
|
|
(54 |
) |
Gain on revaluation of put-right liability |
|
|
(603 |
) |
|
|
- |
|
Interest expense - debt and other |
|
|
540 |
|
|
|
247 |
|
Provision for income taxes |
|
|
3,498 |
|
|
|
2,944 |
|
Equity-based awards compensation expense |
|
|
1,846 |
|
|
|
1,651 |
|
Adjusted EBITDA (a non-GAAP measure) |
|
$ |
17,858 |
|
|
$ |
15,642 |
|
RECAP OF PHYSICAL THERAPY OPERATIONS CLINIC COUNT |
|
Date |
Number of Clinics |
|
|
|
564 |
|
575 |
|
579 |
|
591 |
|
|
|
601 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005172/en/
email: chendrickson@usph.com
(713) 297-7000
Three
(817) 778-8424
Source:
FAQ
What were the earnings per share for USPH in Q1 2022?
How much did USPH's revenue increase in Q1 2022?
What was the net income for USPH for the first quarter of 2022?
What is the quarterly dividend declared by USPH?